化疗所致恶心呕吐的相关进展
Progress in Chemotherapy-Induced Nausea and Vomiting
DOI: 10.12677/ACM.2024.141050, PDF,   
作者: 张宇恒：青海大学研究生院，青海 西宁；李国元*：青海大学附属医院肿瘤内二科，青海 西宁
关键词: CINV；止吐药；奥氮平；止吐；CINV； Antiemetic Drugs； Ondansetron； Stop Vomiting
摘要: 化疗引起的恶心和呕吐(CINV)是化疗的严重副作用，对肿瘤患者的生活质量产生负面影响，并与化疗的致吐风险有关，因此预防和治疗CINV就显得至关重要。结合国内外关于CINV指南最新的变化，本文从CINV的病理生理学、CINV的相关止吐药物，以及中高致吐性CINV的相关止吐方案、奥氮平防治CINV的进展等方面予以综述。本文就CINV的发生机制、分型、影响因素、致吐药物分级和止吐药进行综述，并重点阐述止吐药的研究进展，旨在为肿瘤科医师提供指导。
Abstract: Chemotherapy-induced nausea and vomiting (CINV) is a severe side effect of chemotherapy that negatively impacts the quality of life for cancer patients and is associated with the risk of emesis. Therefore, the prevention and treatment of CINV are of paramount importance. This article reviews the latest changes in domestic and international CINV guidelines, covering the pathophysiology of CINV, relevant antiemetic drugs for CINV, as well as antiemetic regimens for moderate- to-high emetogenic CINV and the progress in using ondansetron to prevent CINV. The article provides an overview of the mechanisms, classification, influencing factors, drug grading, and antiemetic drugs for CINV, with a focus on advancements in antiemetic research, aiming to provide guidance for on-cologists.
文章引用：张宇恒, 李国元. 化疗所致恶心呕吐的相关进展[J]. 临床医学进展, 2024, 14(1): 345-350. https://doi.org/10.12677/ACM.2024.141050

参考文献

[1] Barušić, A.K. (2022) The Emerging Role of Olanzapine in Paediatric CINV Control: A Review. Medicine, 101, e32116. [Google Scholar] [CrossRef] 
[2] Hesketh, P.J. (2008) Chemotherapy-Induced Nausea and Vomiting. The New England Journal of Medicine, 358, 2482-2494. [Google Scholar] [CrossRef] 
[3] Shankar, A., Roy, S., Malik, A., Julka, P.K. and Rath, G.K. (2015) Prevention of Chemotherapy Induced Nausea and Vomiting in Cancer Patients. Asian Pacific Journal of Cancer Preven-tion, 16, 6207-6213. [Google Scholar] [CrossRef] 
[4] Aapro, M. (2018) CINV: Still Troubling Patients after All These Years. Support Care Cancer, 26, 5-9. [Google Scholar] [CrossRef] [PubMed]
[5] Andrews, P.L. and Sanger, G.J. (2002) Abdominal Vagal Affer-ent Neurones: An Important Target for the Treatment of Gastrointestinal Dysfunction. Current Opinion in Pharmacology, 2, 650-656. [Google Scholar] [CrossRef] 
[6] Navari, R.M. and Aapro, M. (2016) Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. The New England Journal of Medicine, 374, 1356-1367. [Google Scholar] [CrossRef] 
[7] de Boer-Dennert, M., de Wit, R., Schmitz, P.I., et al. (1997) Patient Perceptions of the Side-Effects of Chemotherapy: The Influence of 5HT3 Antagonists. British Journal of Cancer, 76, 1055-1061. [Google Scholar] [CrossRef] [PubMed]
[8] Stern, R.M., Koch, K.L. and Andrews, P.L.R. (2011) Nau-sea: Mechanisms and Management. Oxford, New York.
[9] Navari, R.M. (2009) Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting: Focus on Recent Developments. Drugs, 69, 515-533. [Google Scholar] [CrossRef] [PubMed]
[10] 姜文奇, 巴一, 冯继锋, 等. 肿瘤药物治疗相关恶心呕吐防治中国专家共识(2019年版) [J]. 中国医学前沿杂志(电子版), 2019, 11(11): 16-26.
[11] Bymaster, F.P., Falcone, J.F., Bauzon, D., Kennedy, J.S., Schenck, K., DeLapp, N.W. and Cohen, M.L. (2001) Potent Antagonism of 5-HT3 and 5-HT6 Receptors by Olanzapine. European Journal of Pharmacology, 430, 341-349. [Google Scholar] [CrossRef] 
[12] Srivastava, M., Brito-Dellan, N., Davis, M.P., Leach, M. and Lagman, R. (2003) Olanzapine as an Antiemetic in Refractory Nausea and Vomiting in Advanced Cancer. Journal of Pain and Symptom Management, 25, 578-582. [Google Scholar] [CrossRef] 
[13] Passik, S.D., Navari, R.M., Jung, S.H., Nagy, C., Vinson, J., Kirsh, K.L. and Loehrer, P. (2004) A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study. Cancer Investigation, 22, 383-388. [Google Scholar] [CrossRef] 
[14] Navari, R.M., Einhorn, L.H., Passik, S.D., Loehrer Sr., P.J., John-son, C., Mayer, M.L., McClean, J., Vinson, J. and Pletcher, W. (2005) A Phase II Trial of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Hoosier Oncology Group Study. Supportive Care in Cancer, 13, 529-534. [Google Scholar] [CrossRef] [PubMed]
[15] Vimolchalao, V., Sakdejayont, S., Wongchanapai, P., Sukprakun, S., Angspatt, P., Thawinwisan, W., Chenaksara, P., Sriuranpong, V., Vinayanuwatikun, C., Parinyanitikun, N., Poo-vorawan, N. and Tanasanvimon, S. (2020) The Efficacy and Safety of the Addition of Olanzapine to Ondansetron and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy. International Journal of Clinical Oncology, 25, 396-402. [Google Scholar] [CrossRef] [PubMed]
[16] Chiou, T.J., Tzeng, W.F., Wang, W.S., Yen, C.C., Fan, F.S., Liu, J.H. and Chen, P.M. (2000) Comparison of the Efficacy and Safety of Oral Granisetron plus Dexamethasone with Intra-venous Ondansetron plus Dexamethasone to Control Nausea and Vomiting Induced by Moderate/Severe Emetogenic Chemotherapy. Chinese Medical Journal, 63, 729-736.
[17] Patil, V., Prasada, H., Prasad, K. and Shenoy, U.V. (2015) Comparison of Antiemetic Efficacy and Safety of Palonosetron vs Ondansetron in the Prevention of Chemothera-py-Induced Nausea and Vomiting in Children. The Journal of Community and Supportive Oncology, 13, 209-213. [Google Scholar] [CrossRef] [PubMed]
[18] Candelario, N. and Lu, M.L. (2016) Fosaprepitant Dimeglumine for the Management of Chemotherapy-Induced Nausea and Vomiting: Patient Selection and Perspectives. Cancer Management and Research, 8, 77-82. [Google Scholar] [CrossRef] 
[19] Grunberg, S., Chua, D., Maru, A., Dinis, J., DeVandry, S., Boice, J.A., Hardwick, J.S., Beckford, E., Taylor, A., Carides, A., Roila, F. and Herrstedt, J. (2011) Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE. Journal of Clinical Oncology, 29, 1495-1501. [Google Scholar] [CrossRef] 
[20] Mantovani, G., Maccio, A., Esu, S. and Lai, P. (1996) Evidence That Cisplatin Induces Serotoninrelease from Human Peripheral Blood Mononuclear Cells and That Methylprednisolone Inhibits This Effect. European Journal of Cancer, 32, 1983-1985. [Google Scholar] [CrossRef] [PubMed]
[21] Ho, C.M., Ho, S.T., Wang, J.J., et al. (2004) Dexamethasone Has a Central Antiemetic Mechanism in Decerebrated Cats. Anesthesia & Analgesia, 99, 734-739. [Google Scholar] [CrossRef] 
[22] Ibrahim, E.M., Al-Idrissi, H.Y., Ibrahim, A., et al. (1986) Antiemetic Efficacy of High-Dose Dexamethasone: Randomized, Double-Blind, Crossover Study with High-Dose Metoclopramide in Patients Receiving Cancer Chemotherapy. European Journal of Cancer and Clinical On-cology, 22, 283-288. [Google Scholar] [CrossRef] [PubMed]
[23] Ioannidis, J.P., Hesketh, P.J. and Lau, J. (2000) Contribution of Dexamethasone to Control Ofchemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence. Journal of Clinical Oncology, 18, 3409-3422. [Google Scholar] [CrossRef] 
[24] Jordan, K., Kasper, C. and Schmoll, H.J. (2005) Chemothera-py-Induced Nausea and Vomiting: Current and New Standards in the Antiemetic Prophylaxis and Treatment. European Journal of Cancer, 41, 199-205. [Google Scholar] [CrossRef] [PubMed]
[25] Zaglama, N.E., Rosenblum, S.L., Sartiano, G.P., et al. (1986) Sin-gle, High-Dose Intravenous Dexamethasone as an Antiemetic in Cancer Chemotherapy. Oncology, 43, 27-32. [Google Scholar] [CrossRef] [PubMed]

为你推荐